表紙:嚢胞性線維症:情報分析レポート(2010年~2021年)
市場調査レポート
商品コード
1024237

嚢胞性線維症:情報分析レポート(2010年~2021年)

Cystic Fibrosis - Deals Analytics Report, 2010 to 2021

出版日: | 発行: GervanoRA Data Services LLP | ページ情報: 英文 60 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
嚢胞性線維症:情報分析レポート(2010年~2021年)
出版日: 2021年08月11日
発行: GervanoRA Data Services LLP
ページ情報: 英文 60 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、嚢胞性線維症に焦点を当て、嚢胞性線維症の世界の治療状況を分析するほか、セグメント別の資本取引の動向、主要企業の分析、資本取引に関するケーススタディなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 取引の分析

  • 協定
  • 提携
  • 合併・買収
  • 資金調達
  • ライセンシング契約
  • アライアンス

第4章 取引額および地域

第5章 主要企業の分析

第6章 年次頻度の分析

第7章 ケーススタディ:主要5件

第8章 略語

図表

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
  • TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
  • FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 03: CYSTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
  • FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
  • FIGURE 06: INCREASING AGREEMENT DEALS
目次
Product Code: GERPD001

GervanoRA's 'Cystic Fibrosis Deals Activity Report, 2010-2021' has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. CYSTIC FIBROSIS AGREEMENTS
  • 3.2. CYSTIC FIBROSIS COLLABORATIONS
  • 3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
  • 3.4. CYSTIC FIBROSIS FINANCING- GRANT AND FUNDING DEALS
  • 3.5. CYSTIC FIBROSIS LICENSING DEALS
  • 3.6. CYSTIC FIBROSIS ALLIANCE DEAL

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

8. ABBREVIATIONS